RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement
Globenewswire·2025-11-18 14:30
Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the commencement of a Regulation D, Rule 506(c) exempt offering of securities, across the three entities of the RespireRx Group, RespireRx, EndeavourRx LLC and ResolutionRx Ltd (collectively, the RespireRx Group). The targeted ...